Johnson & Johnson (NYSE:JNJ) Shares Acquired by Daiwa Securities Group Inc.

Posted by Defense World Staff on Aug 1st, 2023

Daiwa Securities Group Inc. lifted its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 7.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 276,299 shares of the company’s stock after purchasing an additional 18,687 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Johnson & Johnson were worth $42,826,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the stock. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA raised its stake in shares of Johnson & Johnson by 1.6% during the first quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 366,274 shares of the company’s stock worth $56,772,000 after purchasing an additional 5,633 shares during the last quarter. LMG Wealth Partners LLC raised its stake in shares of Johnson & Johnson by 10.8% during the first quarter. LMG Wealth Partners LLC now owns 14,480 shares of the company’s stock worth $2,244,000 after purchasing an additional 1,412 shares during the last quarter. Easterly Investment Partners LLC raised its position in Johnson & Johnson by 46.7% in the first quarter. Easterly Investment Partners LLC now owns 152,958 shares of the company’s stock worth $23,709,000 after acquiring an additional 48,659 shares in the last quarter. Jackson Grant Investment Advisers Inc. raised its position in Johnson & Johnson by 1.8% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 14,807 shares of the company’s stock worth $2,295,000 after acquiring an additional 258 shares in the last quarter. Finally, V Wealth Advisors LLC raised its position in Johnson & Johnson by 2.7% in the first quarter. V Wealth Advisors LLC now owns 11,819 shares of the company’s stock worth $1,832,000 after acquiring an additional 308 shares in the last quarter. Hedge funds and other institutional investors own 67.57% of the company’s stock.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the sale, the vice president now directly owns 102,696 shares in the company, valued at approximately $17,491,182.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, EVP Kathryn E. Wengel sold 12,465 shares of the business’s stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the completion of the transaction, the executive vice president now owns 65,934 shares in the company, valued at approximately $10,549,440. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Peter Fasolo sold 20,000 shares of the business’s stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the transaction, the vice president now owns 102,696 shares of the company’s stock, valued at approximately $17,491,182.72. The disclosure for this sale can be found here. Insiders have sold 47,163 shares of company stock worth $7,928,856 in the last three months. 0.20% of the stock is owned by insiders.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ opened at $167.53 on Tuesday. The company has a market cap of $435.37 billion, a P/E ratio of 33.91, a PEG ratio of 2.93 and a beta of 0.55. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.85 and a current ratio of 1.07. Johnson & Johnson has a one year low of $150.11 and a one year high of $181.04. The business’s 50-day simple moving average is $161.97 and its 200 day simple moving average is $161.07.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its earnings results on Thursday, July 20th. The company reported $2.80 EPS for the quarter, beating the consensus estimate of $2.62 by $0.18. Johnson & Johnson had a return on equity of 37.01% and a net margin of 13.35%. The business had revenue of $25.53 billion for the quarter, compared to the consensus estimate of $24.63 billion. During the same period last year, the business posted $2.59 EPS. The company’s revenue was up 6.3% on a year-over-year basis. On average, sell-side analysts forecast that Johnson & Johnson will post 10.76 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 7th. Shareholders of record on Monday, August 28th will be issued a dividend of $1.19 per share. The ex-dividend date of this dividend is Friday, August 25th. This represents a $4.76 annualized dividend and a yield of 2.84%. Johnson & Johnson’s dividend payout ratio is presently 96.36%.

Analyst Ratings Changes

Several research firms have issued reports on JNJ. Morgan Stanley reiterated an “equal weight” rating and issued a $187.00 price objective on shares of Johnson & Johnson in a research report on Friday, July 21st. StockNews.com began coverage on Johnson & Johnson in a research report on Thursday, May 18th. They issued a “strong-buy” rating for the company. Raymond James increased their price objective on Johnson & Johnson from $181.00 to $184.00 and gave the stock an “outperform” rating in a research report on Monday, July 24th. TheStreet cut Johnson & Johnson from a “b” rating to a “c+” rating in a research report on Friday, May 19th. Finally, Citigroup started coverage on Johnson & Johnson in a research report on Tuesday, May 30th. They issued a “buy” rating and a $185.00 price target for the company. Eight analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $171.60.

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.